𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sclerosing mucoepidermoid carcinoma of the esophagus with intraepithelial carcinoma or dysplastic epithelium

✍ Scribed by Ken-Ichi Mafune; Yoichi Tanaka; Kichishiro Fujita; Kaiyo Takubo

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
789 KB
Volume
58
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis

Mucoepidermoid carcinoma of the esophagus is a particularly rare lesion, and only 24 cases have been reported in the English literature. Using histochemical methods, we identified four (3.1%) of 135 resected primary esophageal cancers as mucoepidermoid carcinomas. Gross examination of these four tumors disclosed sclerosing submucosal infiltration with shallow surface ulceration, which had appeared as a funnel-shaped constriction on esophagram. The intraepithelial spread of the tumor in two cases and the close relationship between foci of invading carcinoma and regions of dysplastic epithelium in the remaining two cases suggest that esophageal mucoepidermoid carcinoma may originate in the squamous epithelium. Although mucoepidermoid carcinoma should theoretically offer a fair prognosis, the outcome for patients with this lesion has generally been as poor as patients with typical squamous cell carcinoma. This further implies that mucoepidermoid carcinomas may arise from the squamous epithelium.

πŸ“œ SIMILAR VOLUMES

CD44 expression in dysplastic epithelium
CD44 expression in dysplastic epithelium and squamous-cell carcinoma of the esophagus
✍ G. Dean Roye; Russell B. Myers; David Brown; Robert Poczatek; Samuel W. Beenken; πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 French βš– 581 KB

The molecular events involved in the development of esophageal dysplasia and carcinoma are poorly understood. We examined the expression of CD44, a cell-adhesion molecule, in normal and dysplastic epithelia and in squamous-cell carcinoma (SCC) of the esophagus. A monoclonal antibody (MAb) which reco

Surgical treatment for carcinoma of the
Surgical treatment for carcinoma of the thoracic esophagus with major involvement in the neck or upper mediastinum
✍ Matsubara, Toshiki; Ueda, Mamoru; Nagao, Narutoshi; Takahashi, Takashi; Nakajima πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 47 KB πŸ‘ 2 views

## Background and Objectives: In carcinoma of the thoracic esophagus, most surgeons consider that esophagectomy is contraindicated in patients with clinical evidence of major extraesophageal involvement in the lower neck or peritracheal regions. However, metastases to these regions are commonly fo

Preoperative induction of CPT-11 and cis
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction
✍ Jaffer A. Ajani; Garrett Walsh; Ritsuko Komaki; Jeff Morris; Stephen G. Swisher; πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 96 KB

## Abstract ## BACKGROUND Patients with localized esophageal carcinoma often develop locoregional and distant disease recurrence. The current study investigated the outcome of a new chemotherapy combination as induction therapy before chemoradiotherapy. ## METHODS Forty‐three patients with resec

Phase II clinical trial with 5-fluoroura
Phase II clinical trial with 5-fluorouracil, recombinant interferon-Ξ±-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus
✍ Scott Wadler; Hilda Haynes; Jonathan J. Beitler; Xiaoping Hu; Stanley Fell; Marg πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 393 KB πŸ‘ 1 views

## Background: Recombinant interferon-alpha (ifn) augments the cytotoxicity of both 5-fluorouracil (5-fu) and cisplatin in vitro. a phase ii study of 5-fu and ifn resulted in response rates of 25-27% in patients with metastatic esophageal carcinoma. ## Methods: A phase ii trial was initiated to d